APPROPRIATE USE OF IMMUNOGLOBULINS IN POLAND - Key Considerations and Treatment Paradigms
Common Position of Scientific Societies: Polish Society of Dermatology (PTD), Polish Society for Fundamental and Clinical Immunology (PTiDiK), Polish Society of Paediatric Oncology and Haematology (PTOHD) Background and Objectives This paper aims to analyse, assess and appraise appropriate use of Normal Polyvalent Immunoglobulins (IgGs) across multiple indications, wherever these therapies are known to be used and have been proven to be an effective therapeutic modality. This assessment is based on a framework proposed by a group of international experts in the recent Green Paper „Appropriate Use of Immunoglobulins in Europe”.1 Based on a systematic application of the framework’s criteria to all IgG conditions and diseases, this paper presents a short-list of indications, where IgG use is appropriate, together with a guidance on optimal therapeutic paradigms. As such, this paper is aimed to assist the clinical community and policy makers in navigating the extremely complex clinical landscape of rare and ultra-rare diseases and conditions, which are either immune-mediated or stem from deficient, dysregulated or dysfunctional immune system. Some of the indications considered in this study are currently not registered for IgG use in Poland or, if registered, not fully covered with reimbursement. In cases where IgG use in such conditions or diseases is found to be appropriate, this study may be also considered by the relevant regulatory and/or HTA bodies as a contribution towards reassessment or reappraisal.
Authors
- Sylwia Kołtan (ORCID: https://orcid.org/0000-0001-7663-6580)
- Wojciech Michal Mlynarski (ORCID: https://orcid.org/0000-0003-2714-5851)
- Rafał Czajkowski (ORCID: https://orcid.org/0000-0003-3418-1252)
- Maciej Pastuszczak (ORCID: https://orcid.org/0000-0001-7241-9685)
- Katarzyna Drabko (ORCID: https://orcid.org/0000-0002-7094-9129)
- Karina Jahnz‐Różyk (ORCID: https://orcid.org/0000-0002-3505-1858)
- Edyta Heropolitańska–Pliszka (ORCID: https://orcid.org/0000-0001-5519-2730)
- Ewa Więsik–Szewczyk (ORCID: https://orcid.org/0000-0001-8509-4453)
- Małgorzata Pac (ORCID: https://orcid.org/0000-0003-2071-3297)
- Iwona Hus (ORCID: https://orcid.org/0000-0002-6096-4093)
- Ewelina Grywalska (ORCID: https://orcid.org/0000-0002-0451-4741)
- Marta Lipowska (ORCID: https://orcid.org/0000-0002-9214-8867)
- Jacek Cezary Szepietowski (ORCID: https://orcid.org/0000-0003-0766-6342)
- Anna Kostera‐Pruszczyk (ORCID: https://orcid.org/0000-0002-7309-1914)
- Jacek Roliński (ORCID: https://orcid.org/0000-0003-4841-6120)
- Jan Styczyński (ORCID: https://orcid.org/0000-0002-3158-119X)
- Tomasz Kluszczyński (ORCID: https://orcid.org/0009-0005-1346-9291)
Institutions
- San Antonio College (US)
- Medical University of Lublin (PL)
- Ministry of Internal Affairs of the Republic of Tajikistan (TJ)
- Medical University of Silesia (PL)
- Medical University of Warsaw (PL)
- Nicolaus Copernicus University (PL)
- Wroclaw Medical University (PL)
- Military Institute (RU)
- Service Public Fédéral Intérieur (BE)
- Children's Memorial Health Institute (PL)
- Medical University of Lodz (PL)
Publication Details
- Journal
- Journal of Health Policy & Outcomes Research
- Published
- 2025-04-17
- DOI
- https://doi.org/10.7365/jhpor.2025.1.6
- Primary Topic
- Chronic Lymphocytic Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00